Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

P Sinha, VE Kerchberger, A Willmore… - The Lancet …, 2023 - thelancet.com
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …
被引用次数：32 相关文章

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

P Sinha, VE Kerchberger, A Willmore… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.

P Sinha, VE Kerchberger, A Willmore… - The Lancet …, 2023 - europepmc.org
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

P Sinha, VE Kerchberger, A Willmore… - The Lancet Respiratory …, 2023 - Elsevier
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

P Sinha, VE Kerchberger, A Willmore… - The Lancet …, 2023 - thelancet.com
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

P Sinha, VE Kerchberger, A Willmore… - The Lancet …, 2023 - profiles.wustl.edu
Background: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has
contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular …